Emil D. Kakkis

2016

In 2016, Emil D. Kakkis earned a total compensation of $4.4M as President and Chief Executive Officer at Ultragenyx Pharmaceutical, a 18% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$340,320
Option Awards$2,722,360
Salary$567,200
Stock Awards$755,099
Other$38,383
Total$4,423,362

Kakkis received $2.7M in option awards, accounting for 62% of the total pay in 2016.

Kakkis also received $340.3K in non-equity incentive plan, $567.2K in salary, $755.1K in stock awards and $38.4K in other compensation.

Rankings

In 2016, Emil D. Kakkis' compensation ranked 1,945th out of 14,075 executives tracked by ExecPay. In other words, Kakkis earned more than 86.2% of executives.

ClassificationRankingPercentile
All
1,945
out of 14,075
86th
Division
Manufacturing
668
out of 5,489
88th
Major group
Chemicals And Allied Products
188
out of 1,895
90th
Industry group
Drugs
134
out of 1,538
91st
Industry
Pharmaceutical Preparations
107
out of 1,176
91st
Source: SEC filing on April 28, 2017.

Kakkis' colleagues

We found five more compensation records of executives who worked with Emil D. Kakkis at Ultragenyx Pharmaceutical in 2016.

2016

Karah Parschauer

Ultragenyx Pharmaceutical

General Counsel

2016

Jayson Dallas

Ultragenyx Pharmaceutical

Chief Commercial Officer and Executive Vice President

2016

John Pinion

Ultragenyx Pharmaceutical

Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research

2016

Shalini Sharp

Ultragenyx Pharmaceutical

Chief Financial Officer

2016

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officers and Executive Vice President

News

In-depth

You may also like